Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -2067.81% is 417% below its 1-year average of -400.27%, near the low end of its 1-year range (-2067.81%–-220.55%).
479.68% below its 12-month average of -356.72%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -569.09%.
RETURN ON EQUITY (ROE)
-2067.81%
RETURN ON EQUITY (ROE) AVG TTM
-356.72%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-479.68%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-4822.19%
vs the sector median at left
Actuate Therapeutics Inc
Market Cap
$18.59M
Return on Equity (ROE)
-2067.81%
TTM Avg
-356.72%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$18.67M
Return on Equity (ROE)
-75.34%
TTM Avg
-0.67%
3Y Avg
-77.39%
5Y Avg
-61.36%
Market Cap
$18.03M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
Market Cap
$17.99M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$19.43M
Return on Equity (ROE)
-136.36%
TTM Avg
-41.80%
3Y Avg
-1184.66%
5Y Avg
-795.29%
Market Cap
$17.11M
Return on Equity (ROE)
-54.45%
TTM Avg
-33.23%
3Y Avg
-44.23%
5Y Avg
-52.50%
Market Cap
$17.04M
Return on Equity (ROE)
-34.50%
TTM Avg
-796.82%
3Y Avg
-138.82%
5Y Avg
-407.45%
Market Cap
$17.17M
Return on Equity (ROE)
-71.57%
TTM Avg
-65.12%
3Y Avg
-85.39%
5Y Avg
-90.29%
Market Cap
$20.47M
Return on Equity (ROE)
-351.86%
TTM Avg
-122.41%
3Y Avg
-86.06%
5Y Avg
-64.41%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Actuate Therapeutics Inc (ACTU) | $18.59M | -2067.81% | -356.72% | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.67M | -75.34% | -0.67% | -77.39% | -61.36% |
| Cosmos Health Inc. (COSM)vs › | $18.03M | -117.98% | -84.94% | -64.05% | -76.29% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | N/A | -3014.83% | -1589.49% | -1032.64% |
| P3 Health Partners Inc. (PIII)vs › | $19.43M | -136.36% | -41.80% | -1184.66% | -795.29% |
| Lipocine Inc. (LPCN)vs › | $17.11M | -54.45% | -33.23% | -44.23% | -52.50% |
| PAVmed Inc. (PAVM)vs › | $17.04M | -34.50% | -796.82% | -138.82% | -407.45% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | -71.57% | -65.12% | -85.39% | -90.29% |
| NextCure, Inc. (NXTC)vs › | $20.47M | -351.86% | -122.41% | -86.06% | -64.41% |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | -125.30% | 118.50% | 7030.24% | 4638.47% |
ROE
-2067.8%
ROA
-393.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -569.09% |
| 2025-12-31 | -280.51% |
| 2025-09-30 | -220.55% |
| 2024-09-30 | -530.94% |
